Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NT-Z001
- Development stage
- Preclinical
- Lead developer
- Navega Therapeutics
- Modality
- Small Molecules, Gene Therapies
- Administration
- Intrathecal
01
Overview
NT-Z001 is a de-immunized epigenetic gene therapy developed by Navega Therapeutics for the non-opioid treatment of chronic pain. It targets a gain-of-function mutation in the SCN9A gene, which encodes the Nav1.7 voltage-gated sodium channel alpha subunit, implicated in inherited erythromelalgia, small fiber neuropathy, and other chronic debilitating pain disorders. The therapy uses an AI-enabled zinc-finger epigenome regulation platform to down-regulate Nav1.7 expression, thereby modulating pain signal transmission without opioid-related risks or addiction potential. It is delivered via an adeno-associated virus (AAV) vector (specifically AAV9). The drug is currently in preclinical development with plans for Phase I clinical trials.
- Other names
- NT Z001
02
Targets
SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on NT-Z001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NT-Z001.